FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912182619> ?p ?o ?g. }

• W2912182619 endingPage "l67" @default.
• W2912182619 startingPage "l67" @default.
• W2912182619 abstract "Abstract Objective To compare the effectiveness and safety of three non-tumour necrosis factor (TNF) α inhibitors (rituximab, abatacept, and tocilizumab) in the treatment of rheumatoid arthritis. Design Population based prospective study. Setting 53 university and 54 non-university clinical centres in France. Participants 3162 adults (>18 years) with rheumatoid arthritis according to 1987 American College of Rheumatology criteria, enrolled in one of the three French Society of Rheumatology registries; who had no severe cardiovascular disease, active or severe infections, or severe immunodeficiency, with follow-up of at least 24 months. Intervention Initiation of intravenous rituximab, abatacept, or tocilizumab for rheumatoid arthritis. Main outcome measure The primary outcome was drug retention without failure at 24 months. Failure was defined as all cause death; discontinuation of rituximab, abatacept, or tocilizumab; initiation of a new biologic or a combination of conventional disease modifying antirheumatic drugs; or increase in corticosteroid dose >10 mg/d compared with baseline at two successive visits. Because of non-proportional hazards, treatment effects are presented as life expectancy difference without failure (LED wf ), which measures the difference between average duration of survival without failure. Results Average durations of survival without failure were 19.8 months for rituximab, 15.6 months for abatacept, and 19.1 months for tocilizumab. Average durations were greater with rituximab (LED wf 4.1, 95% confidence interval 3.1 to 5.2) and tocilizumab (3.5, 2.1 to 5.0) than with abatacept, and uncertainty about tocilizumab compared with rituximab was substantial (−0.7, −1.9 to 0.5). No evidence was found of difference between treatments for mean duration of survival without death, presence of cancer or serious infections, or major adverse cardiovascular events. Conclusion Among adults with refractory rheumatoid arthritis followed-up in routine practice, rituximab and tocilizumab were associated with greater improvements in outcomes at two years compared with abatacept." @default.
• W2912182619 created "2019-02-21" @default.
• W2912182619 creator A5008108487 @default.
• W2912182619 creator A5008811878 @default.
• W2912182619 creator A5022109878 @default.
• W2912182619 creator A5025160491 @default.
• W2912182619 creator A5032316254 @default.
• W2912182619 creator A5034097548 @default.
• W2912182619 creator A5051196993 @default.
• W2912182619 creator A5060019340 @default.
• W2912182619 creator A5062958039 @default.
• W2912182619 creator A5076446601 @default.
• W2912182619 creator A5076759724 @default.
• W2912182619 creator A5077099389 @default.
• W2912182619 creator A5078390860 @default.
• W2912182619 creator A5080881858 @default.
• W2912182619 creator A5086242828 @default.
• W2912182619 creator A5086550404 @default.
• W2912182619 date "2019-01-24" @default.
• W2912182619 modified "2023-10-17" @default.
• W2912182619 title "Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study" @default.
• W2912182619 cites W1966714873 @default.
• W2912182619 cites W1967360492 @default.
• W2912182619 cites W2009187570 @default.
• W2912182619 cites W2014709373 @default.
• W2912182619 cites W2024644107 @default.
• W2912182619 cites W2034806082 @default.
• W2912182619 cites W2079590652 @default.
• W2912182619 cites W2100678780 @default.
• W2912182619 cites W2102207725 @default.
• W2912182619 cites W2102593826 @default.
• W2912182619 cites W2108519284 @default.
• W2912182619 cites W2110818436 @default.
• W2912182619 cites W2114308202 @default.
• W2912182619 cites W2124670599 @default.
• W2912182619 cites W2133668754 @default.
• W2912182619 cites W2139323151 @default.
• W2912182619 cites W2141323245 @default.
• W2912182619 cites W2144985400 @default.
• W2912182619 cites W2151981428 @default.
• W2912182619 cites W2152619496 @default.
• W2912182619 cites W2167061160 @default.
• W2912182619 cites W2298338128 @default.
• W2912182619 cites W2303252670 @default.
• W2912182619 cites W2404262996 @default.
• W2912182619 cites W2557395888 @default.
• W2912182619 cites W2617476695 @default.
• W2912182619 cites W2790381016 @default.
• W2912182619 cites W4210968471 @default.
• W2912182619 doi "https://doi.org/10.1136/bmj.l67" @default.
• W2912182619 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6344892" @default.
• W2912182619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30679233" @default.
• W2912182619 hasPublicationYear "2019" @default.
• W2912182619 type Work @default.
• W2912182619 sameAs 2912182619 @default.
• W2912182619 citedByCount "73" @default.
• W2912182619 countsByYear W29121826192019 @default.
• W2912182619 countsByYear W29121826192020 @default.
• W2912182619 countsByYear W29121826192021 @default.
• W2912182619 countsByYear W29121826192022 @default.
• W2912182619 countsByYear W29121826192023 @default.
• W2912182619 crossrefType "journal-article" @default.
• W2912182619 hasAuthorship W2912182619A5008108487 @default.
• W2912182619 hasAuthorship W2912182619A5008811878 @default.
• W2912182619 hasAuthorship W2912182619A5022109878 @default.
• W2912182619 hasAuthorship W2912182619A5025160491 @default.
• W2912182619 hasAuthorship W2912182619A5032316254 @default.
• W2912182619 hasAuthorship W2912182619A5034097548 @default.
• W2912182619 hasAuthorship W2912182619A5051196993 @default.
• W2912182619 hasAuthorship W2912182619A5060019340 @default.
• W2912182619 hasAuthorship W2912182619A5062958039 @default.
• W2912182619 hasAuthorship W2912182619A5076446601 @default.
• W2912182619 hasAuthorship W2912182619A5076759724 @default.
• W2912182619 hasAuthorship W2912182619A5077099389 @default.
• W2912182619 hasAuthorship W2912182619A5078390860 @default.
• W2912182619 hasAuthorship W2912182619A5080881858 @default.
• W2912182619 hasAuthorship W2912182619A5086242828 @default.
• W2912182619 hasAuthorship W2912182619A5086550404 @default.
• W2912182619 hasBestOaLocation W29121826191 @default.
• W2912182619 hasConcept C126322002 @default.
• W2912182619 hasConcept C188816634 @default.
• W2912182619 hasConcept C2777178219 @default.
• W2912182619 hasConcept C2777226972 @default.
• W2912182619 hasConcept C2777575956 @default.
• W2912182619 hasConcept C2778715236 @default.
• W2912182619 hasConcept C2779338263 @default.
• W2912182619 hasConcept C2779605438 @default.
• W2912182619 hasConcept C2779722408 @default.
• W2912182619 hasConcept C2780653079 @default.
• W2912182619 hasConcept C2908647359 @default.
• W2912182619 hasConcept C71924100 @default.
• W2912182619 hasConcept C99454951 @default.
• W2912182619 hasConceptScore W2912182619C126322002 @default.
• W2912182619 hasConceptScore W2912182619C188816634 @default.
• W2912182619 hasConceptScore W2912182619C2777178219 @default.
• W2912182619 hasConceptScore W2912182619C2777226972 @default.
• W2912182619 hasConceptScore W2912182619C2777575956 @default.
• W2912182619 hasConceptScore W2912182619C2778715236 @default.

• next